ArticleThe oncologist2016

Broad Detection of Alterations Predicted to Confer Lack of Benefit From EGFR Antibodies or Sensitivity to Targeted Therapy in Advanced Colorectal Cancer.

Andrew Rankin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.